CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
ItalianoPILERI, Alessandro
Pubblicazioni
Risultati 1 - 20 di 98 (tempo di esecuzione: 0.001 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. | 1988 | Dianzani U; Pileri A; Boccadoro M; Palumbo A; Pioppo P; Bianchi A; Camponi A; Fossati G; Battaglio S; Massaia M |
| 2 | Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. | 1998 | Majolino I; Corradini P; Scimè R; Santoro A; Tarella C; Cavallaro AM; Palumbo A; Indovina A; Caracciolo D; Boccadoro M; Marcenò R; Pileri A. |
| 3 | Altered expression of growth-regulated protoncogenes in human malignant plasma cells. | 1989 | Palumbo A; Pileri A; Dianzani U; Massaia M; Boccadoro M; Calabretta B |
| 4 | An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. | 1999 | Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A |
| 5 | Analysis of the breakpoint cluster region in essential thrombocythemia. | 1990 | Corradini P; Palumbo A; Battaglio S; Ponzio G; Boccadoro M; Pileri A |
| 6 | Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. | 1997 | Campana S; Corradini P; Astolfi M; Ladetto M; Cinque F; Novero D; Tarella C; Pileri A. |
| 7 | Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders. | 1986 | Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E. |
| 8 | Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. | 1987 | Ferrero D; De Fabritiis P; Amadori S; De Felice L; Gallo E; Meloni G; Pregno P; Pulsoni A; Simone F; Tarella C; Pileri A; Rovera G; Mandelli F |
| 9 | Biology of the human myeloma cell population. I.Macromolecular characteristics. | 1978 | Hulling, N; Boccadoro, M; Masera, P; Pileri, A |
| 10 | Both early and committed progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. | 1995 | C. TARELLA; BENEDETTI G; CARACCIOLO D; CASTELLINO C; CHERASCO C; BONDESAN P; OMEDE' P; RUGGIERI D; GIANNI AM; PILERI A |
| 11 | Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short interval between drug courses severely impair progenitor mobilization. | 1995 | C. TARELLA; CARACCIOLO D; GAVAROTTI P; BONDESAN P; CHERASCO C; OMEDE' P; BREGNI M; SIENA S; GIANNI AM; PILERI A. |
| 12 | Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. | 1996 | Corradini P; Ladetto M; Astolfi M; Voena C; Tarella C; Bacigalupo A; Pileri A |
| 13 | Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. | 1990 | Tarella C; Ferrero D; Siena S; Gallo E; Bondesan P; Bregni M; Pileri A; Gianni AM. |
| 14 | Consolidation treatment with dexamethasone and alpha-2b recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy. | 1990 | Palumbo A; Garino A; Frieri R; Gallone G; Boccadoro M; Pileri A |
| 15 | Conventional induction treatments do not influence overall survival in multiple myeloma. | 1997 | Boccadoro M; Palumbo A; Argentino C; Dominietto A; Frieri R; Avvisati G; Comotti B; LautaVM; Liberati M; Marmont F; Musto P; Tribalto M; Pileri A. |
| 16 | Current therapeutic options for multiple myeloma. | 1996 | Pileri A; Palumbo A; Boccadoro M |
| 17 | Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma. | 1994 | Palumbo A; Boccadoro M; Triolo S; Bruno B; Pileri A |
| 18 | Cytofluorimetric evaluation of plasma cell proliferative activity in monoclonal gammopathies. | 1998 | Triolo R; Omede P; Giaretta F; Ravaglia R; Battaglio S; Palumbo A; Dominietto A; Argentino C; Triolo S; Pileri A; Boccadoro M. |
| 19 | Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue | 2018 | Ciavarella, S.; Vegliante, M.C.; Fabbri, M.; De Summa, S.; Melle, F.; Motta, G.; De Iuliis, V.; Opinto, G.; Enjuanes, A.; Rega, S.; Gulino, A.; Agostinelli, C.; Scattone, A.; Tommasi, S.; Mangia, A.; Mele, F.; Simone, G.; Zito, A.F.; Ingravallo, G.; Vitolo, U.; Chiappella, A.; Tarella, C.; Gianni, A.M.; Rambaldi, A.; Zinzani, P.L.; Casadei, B.; Derenzini, E.; Loseto, G.; Pileri, A.; Tabanelli, V.; Fiori, S.; Rivas-Delgado, A.; López-Guillermo, A.; Venesio, T.; Sapino, A.; Campo, E.; Tripodo, C.; Guarini, A.; Pileri, S.A. |
| 20 | Dose- intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. | 1999 | Palumbo A; Triolo S; Argentino C; Bringhen S; Dominietto A; Rus C; Omedè P; Tarella C; Pileri A; Boccadoro M |
Dettaglio
PILERI, Alessandro
EX-Dip. MEDICINA ED ONCOLOGIA SPERIMENTALE-(1900/2013)
Copyright © 2020